Merus (NASDAQ:MRUS – Get Rating) had its target price raised by equities researchers at HC Wainwright from $40.00 to $48.00 in a research report issued to clients and investors on Friday, The Fly reports. HC Wainwright’s target price would suggest a potential upside of 155.18% from the company’s previous close.
Several other equities analysts also recently weighed in on MRUS. Citigroup lifted their target price on Merus from $38.00 to $47.00 and gave the company a “buy” rating in a research report on Monday, April 17th. EF Hutton Acquisition Co. I reiterated a “buy” rating and set a $35.00 price objective on shares of Merus in a research note on Friday, April 14th. BMO Capital Markets raised their target price on shares of Merus from $47.00 to $49.00 in a research note on Tuesday, April 18th. SVB Securities upped their price target on shares of Merus from $35.00 to $48.00 and gave the stock an “outperform” rating in a research report on Monday, April 17th. Finally, Stifel Nicolaus raised their price objective on shares of Merus from $34.00 to $44.00 and gave the company a “buy” rating in a research report on Tuesday, April 18th. One equities research analyst has rated the stock with a sell rating and nine have assigned a buy rating to the company’s stock. According to data from MarketBeat, Merus has a consensus rating of “Moderate Buy” and an average target price of $42.67.
Merus Trading Down 0.6 %
Shares of MRUS opened at $18.81 on Friday. The firm has a fifty day simple moving average of $19.38 and a two-hundred day simple moving average of $17.62. The firm has a market cap of $875.23 million, a PE ratio of -6.49 and a beta of 0.75. Merus has a 1-year low of $12.03 and a 1-year high of $30.81.
Merus (NASDAQ:MRUS – Get Rating) last posted its quarterly earnings data on Tuesday, February 28th. The biotechnology company reported ($1.81) EPS for the quarter, missing analysts’ consensus estimates of ($0.84) by ($0.97). The firm had revenue of $10.67 million for the quarter, compared to analysts’ expectations of $8.34 million. Merus had a negative net margin of 315.48% and a negative return on equity of 44.86%. As a group, research analysts forecast that Merus will post -4.2 EPS for the current fiscal year.
Institutional Trading of Merus
Hedge funds have recently bought and sold shares of the stock. Braidwell LP bought a new stake in Merus in the 4th quarter worth approximately $30,910,000. Franklin Resources Inc. lifted its position in Merus by 51.4% during the fourth quarter. Franklin Resources Inc. now owns 1,590,560 shares of the biotechnology company’s stock valued at $24,606,000 after purchasing an additional 539,669 shares during the last quarter. VR Adviser LLC purchased a new position in shares of Merus in the 4th quarter worth $18,970,000. Millennium Management LLC raised its position in shares of Merus by 86.9% during the 2nd quarter. Millennium Management LLC now owns 847,057 shares of the biotechnology company’s stock valued at $19,177,000 after buying an additional 393,771 shares in the last quarter. Finally, Samlyn Capital LLC bought a new stake in shares of Merus in the 3rd quarter valued at approximately $12,372,000. Hedge funds and other institutional investors own 79.34% of the company’s stock.
Merus Company Profile
Merus NV is a clinical-stage immuno-oncology company, which engages in the discovery and development of bispecific antibody therapeutics. Its pipeline includes Biclonics for solid and hematological tumors. The company was founded by Ton Logtenberg and Hennie Hoogenboom on June 16, 2003 and is headquartered in Utrecht, the Netherlands.